The Chemotherapy Induced Peripheral Neuropathy drugs in development market research report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chemotherapy Induced Peripheral Neuropathy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued products.

GlobalData tracks 62 drugs in development for Chemotherapy Induced Peripheral Neuropathy by 61 companies/universities/institutes. The top development phase for Chemotherapy Induced Peripheral Neuropathy is preclinical with 34 drugs in that stage. The Chemotherapy Induced Peripheral Neuropathy pipeline has 58 drugs in development by companies and four by universities/ institutes. Some of the companies in the Chemotherapy Induced Peripheral Neuropathy pipeline products market are: Regulonix, Rudacure and Avantyx Pharmaceuticals.

The key targets in the Chemotherapy Induced Peripheral Neuropathy pipeline products market include Cannabinoid Receptor 2 (CB2 or CX5 or CNR2), Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98), and Sodium Channel Protein Type 9 Subunit Alpha (Neuroendocrine Sodium Channel or Peripheral Sodium Channel 1 or Voltage Gated Sodium Channel Subunit Alpha Nav1.7 or SCN9A).

The key mechanisms of action in the Chemotherapy Induced Peripheral Neuropathy pipeline product include Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Inhibitor with five drugs in Phase I. The Chemotherapy Induced Peripheral Neuropathy pipeline products include 13 routes of administration with the top ROA being Oral and ten key molecule types in the Chemotherapy Induced Peripheral Neuropathy pipeline products market including Small Molecule, and Peptide.

Chemotherapy Induced Peripheral Neuropathy overview

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes, and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy, and type of chemotherapeutic agent.

For a complete picture of Chemotherapy Induced Peripheral Neuropathy’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.